• 1
    Sonnenberg A, Koch TR. Epidemiology of constipation in the United States. Dis Colon Rectum 1989; 32: 18.
  • 2
    Peppas G, Alexiou VG, Mourtzoukou E, Falagas ME. Epidemiology of constipation in Europe and Oceania: a systematic review. BMC Gastroenterol 2008; 8: 5.
  • 3
    Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 2007; 25: 599608.
  • 4
    Talley NJ. Definitions, epidemiology, and impact of chronic constipation. Rev Gastroenterol Disord 2004; 4(Suppl. 2): S310.
  • 5
    Chiarioni G, Whitehead WE, Pezza V, Morelli A, Bassotti G. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology 2006; 130: 65764.
  • 6
    Anonimous. La regola sanitaria salernitana. Rome: Newton Compton, 1998.
  • 7
    Moliere. Le malade imaginaire. Paris: Larousse, 1998.
  • 8
    Wald A, Scarpignato C, Mueller-Lissner S et al. A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. Aliment Pharmacol Ther 2008; 28: 91730.
  • 9
    Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003; 349: 13608.
  • 10
    Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008; 103: 1707.
    Direct Link:
  • 11
    Tack J, Muller-Lissner S, Stanghellini V et al. Diagnosis and treatment of chronic constipation – a European perspective. Neurogastroenterol Motil 2011; 23: 697710.
  • 12
    Surrenti E, Rath DM, Pemberton JH, Camilleri M. Audit of constipation in a tertiary referral gastroenterology practice. Am J Gastroenterol 1995; 90: 14715.
  • 13
    Tantiphlachiva K, Rao P, Attaluri A, Rao SS Digital rectal examination is a useful tool for identifying patients with dyssynergia. Clin Gastroenterol Hepatol 2010; 8: 95560.
  • 14
    Rao SS, Valestin J, Brown CK, Zimmerman B, Schulze K Long-term efficacy of biofeedback therapy for dyssynergic defecation: randomized controlled trial. Am J Gastroenterol 2010; 105: 8906.
  • 15
    Chiarioni G, Whitehead WE, Bassotti G. Randomized controlled trial of biofeedback. Clin Gastroenterol Hepatol 2007; 5: reply 1119.
  • 16
    Gagliardi G, Pescatori M, Altomare DF et al. Results, outcome predictors, and complications after stapled transanal rectal resection for obstructed defecation. Dis Colon Rectum 2008; 51: 18695; discussion 195.
  • 17
    Kamm MA, Dudding TC, Melenhorst J et al. Sacral nerve stimulation for intractable constipation. Gut 2010; 59: 33340.
  • 18
    Shim LS, Jones M, Prott GM, Morris LI, Kellow JE, Malcolm A. Predictors of outcome of anorectal biofeedback therapy in patients with constipation. Aliment Pharmacol Ther 2011; 33: 124551.
  • 19
    Coremans G, Kerstens R, De Pauw M, Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 2003; 67: 829.
  • 20
    Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009; 58: 35765.
  • 21
    Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut 2011; 60: 20918.
  • 22
    Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev 2007; 4, CD003960.
  • 23
    Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009; 29: 31528.
  • 24
    Camilleri M, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 2009; 21: 1256e1117.
  • 25
    Camilleri M, Van Outryve MJ, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation – follow-up of patients from the pivotal studies. Aliment Pharmacol Ther 2010; 32: 111323.
  • 26
    Jarvis CI, Golding J. Lubiprostone (Amitiza) for chronic constipation. Am Fam Physician 2006; 74: 13801.